<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02922231</url>
  </required_header>
  <id_info>
    <org_study_id>251501</org_study_id>
    <nct_id>NCT02922231</nct_id>
  </id_info>
  <brief_title>Post-Marketing Surveillance (Usage Results Study) of RIXUBIS in Adult and Pediatric Patients With Haemophilia B in South Korea</brief_title>
  <official_title>Post-Marketing Surveillance (Usage Results Study) of RIXUBIS in Adult and Pediatric Patients With Haemophilia B in South Korea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxalta now part of Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <brief_summary>
    <textblock>
      Primary: To characterize the safety of RIXUBIS when used under normal clinical care in South
      Korea.

      Secondary: To describe hemostatic effectiveness in subjects receiving RIXUBIS under normal
      clinical care in South Korea.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 6, 2017</start_date>
  <completion_date type="Anticipated">April 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse events (AEs)</measure>
    <time_frame>Throughout the study period of approximately 2 years and 6 months</time_frame>
    <description>Seriousness and severity of AEs, including any inhibitory antibody development and/or anaphylactic reactions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Physician rated effectiveness of RIXUBIS for prophylactic treatment in participants &lt;12 years old</measure>
    <time_frame>Up to 6 months from baseline while on treatment</time_frame>
    <description>Rated on a 4-point ordinal scale: Excellent, Good, Moderate, or none</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant rated effectiveness of RIXUBIS for prophylactic treatment in participants ≥12 years old</measure>
    <time_frame>Up to 6 months from baseline while on treatment</time_frame>
    <description>Rated on a 4-point ordinal scale: Excellent, Good, Moderate, or none</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician rated effectiveness of RIXUBIS for on-demand treatment in participants &lt;12 years old</measure>
    <time_frame>Up to 6 months from baseline while on treatment</time_frame>
    <description>Rated on a 4-point ordinal scale: Excellent, Good, Moderate, or none</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant rated effectiveness of RIXUBIS for on-demand treatment in participants ≥12 years old</measure>
    <time_frame>Up to 6 months from baseline while on treatment</time_frame>
    <description>Rated on a 4-point ordinal scale: Excellent, Good, Moderate, or none</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Hemophilia B</condition>
  <arm_group>
    <arm_group_label>All Study Participants</arm_group_label>
    <description>Participants with congenital hemophilia B (FIX level ≤5%)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RIXUBIS</intervention_name>
    <description>Recombinant Factor IX (rFIX) for intravenous use</description>
    <arm_group_label>All Study Participants</arm_group_label>
    <other_name>Coagulation Factor IX [Recombinant]</other_name>
    <other_name>rFIX</other_name>
    <other_name>BAX326</other_name>
    <other_name>BAX 326</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with hemophilia B in South Korea who have been prescribed RIXUBIS.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Participants with congenital hemophilia B (FIX level ≤5%)

          2. Participant or the participant's legally authorized representative has provided signed
             informed consent.

          3. Participant is indicated for treatment according to the RIXUBIS Korean product
             leaflet.

        Exclusion Criteria:

          1. Participants with known hypersensitivity or presence of any contraindication to
             RIXUBIS or its excipients including hamster protein

          2. Participants with Disseminated Intravascular Coagulation (DIC)

          3. Participants with signs of fibrinolysis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lydia Abad Franch, MD</last_name>
    <role>Study Director</role>
    <affiliation>Baxalta now part of Shire</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Petra Schongrundner</last_name>
    <phone>+43-1201002476031</phone>
    <email>petra.schoengrundner@shire.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Daegu Catholic University Medical Center</name>
      <address>
        <city>Daegu</city>
        <zip>42472</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>DaeJeon Eulji University Hospital</name>
      <address>
        <city>Daejeon</city>
        <zip>35233</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kim Hugh Chul Internal Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>05538</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Korea Hemophilia Foundation</name>
      <address>
        <city>Seoul</city>
        <zip>06641</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2016</study_first_submitted>
  <study_first_submitted_qc>September 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2016</study_first_posted>
  <last_update_submitted>October 19, 2017</last_update_submitted>
  <last_update_submitted_qc>October 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Hemophilia B</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

